Tag: MOGAD
New Hope for MOGAD Patients: ENSPRYNG Demonstrates Unparalleled 68% Reduction in Disabling Relapses
The Phase III METEOROID study, revealed ENSPRYNG (satralizumab) showing reduction in the risk of relapses by 68% in patients compared to placebo,according to...